Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

40%

2 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

2(40.0%)

Phase 2

2(40.0%)

N/A

1(20.0%)

5Total

Phase 3(2)

Phase 2(2)

N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials

NCT03264547Phase 3Completed

A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab

Role: lead

NCT02514681Phase 3Completed

A Phase III Trial of Pertuzumab Retreatment in Previously Pertuzumab Treated Her2-Positive Advanced Breast Cancer

Role: lead

NCT06793553Phase 2Recruiting

Induction Therapy of PTX+BV Followed by Atezolizumab+Nab-PTX for PD-L1+ TNBC

Role: lead

NCT04736576Not ApplicableCompleted

Study to Evaluate Patient Reported Outcome (PRO) and Physical Activity in Japanese Patients With HR+/HER2- Advanced Breast Cancer Treated With Palbociclib Plus Endocrine Therapy or Endocrine Monotherapy

Role: collaborator

NCT01989780Phase 2Completed

Bevacizumab Plus Paclitaxel Optimization Study With Interventional Aintenance Endocrine Therapy in Breast Cancer

Role: lead

All 5 trials loaded